Duchenne muscular dystrophy
Drug research and approvals for duchenne muscular dystrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 62 studies of duchenne muscular dystrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 52 drug trials for it since 2013, FDA has 10 approved and 84 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 62
- Trials authorized in Canada: 52
- FDA orphan approvals: 10
- EU medicines: 2
- Does Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy?NCT07892196 · Not reported · Antalya Training and Research Hospital · starts Jan 2, 2026
- Bone Health in Adults With Duchenne Muscular Dystrophy: A Survey on Osteoporosis, Fractures and Treatment.NCT07890883 · Not reported · Istituto Giannina Gaslini · starts Apr 11, 2024
- Respiratory Progression in Adults With Duchenne Muscular Dystrophy.NCT07879989 · Not reported · Istituto Giannina Gaslini · starts Sep 9, 2025
- A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular DystrophyNCT07856329 · Phase 2 / Phase 3 · Genethon · starts Mar 1, 2021
- Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy PatientsNCT07766980 · Phase 2 · University of Florida · starts Jul 27, 2026
- Safety and Efficacy of KER-065 in Participants With Duchenne Muscular DystrophyNCT07704099 · Phase 2 · Keros Therapeutics, Inc. · starts Sep 25, 2026
- Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD…NCT07674758 · Not reported · Vanderbilt University Medical Center · starts Jan 6, 2025
- A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne…NCT07673809 · Phase 1 / Phase 2 · AO GENERIUM · starts Sep 30, 2025
- Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular DystrophyNCT07642635 · Phase 1 / Phase 2 · Vanderbilt University Medical Center · starts Dec 1, 2026
Approved 9
- Ataluren80S Ribosome modulator
- EteplirsenDystrophin pre-mRNA positive modulator
- ViltolarsenDystrophin pre-mRNA positive modulator
- DeflazacortGlucocorticoid receptor agonist
- GolodirsenDystrophin pre-mRNA positive modulator
- VamoroloneGlucocorticoid receptor agonist
- CasimersenDystrophin pre-mRNA positive modulator
- GivinostatHistone deacetylase inhibitor
- Delandistrogene moxeparvovecDystrophin exogenous gene
Phase 3 12 of 14
- PrednisoneGlucocorticoid receptor agonist
- IdebenoneAntioxidant and mitochondrial electron carrier
- TadalafilPhosphodiesterase 5A inhibitor
- PamrevlumabConnective tissue growth factor inhibitor
- Glutamine
- EdasalonexentNuclear factor NF-kappa-B complex inhibitor
- TamoxifenEstrogen receptor alpha modulator
- SpironolactoneMineralocorticoid receptor antagonist
- UbidecarenoneSupplement
- Creatine
- MetoprololBeta-1 adrenergic receptor antagonist
- EplerenoneMineralocorticoid receptor antagonist
Phase 2 12 of 17
- Sodium nitrate
- SildenafilPhosphodiesterase 5A inhibitor
- EzutromidUtrophin modulator
- Halofuginone
- Brogidirsen
- Sevasemten
- RamaterceptGrowth/differentiation factor 8 inhibitor
- DomagrozumabGrowth/differentiation factor 8 inhibitor
- (-)-epicatechin
- Taldefgrobep alfa
- BisoprololBeta-1 adrenergic receptor antagonist
- Pemirolast
Phase 1 or earlier 11
- GentamicinBacterial 70S ribosome inhibitor
- PentoxifyllineAdenosine A2 receptor antagonist
- IbuprofenCyclooxygenase inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- Isosorbide dinitrateSoluble guanylate cyclase activator
- StamulumabGrowth/differentiation factor 8 inhibitor
- ImlifidaseAntibodies hydrolytic enzyme
- Rimeporide
- Bocidelpar
- Flavocoxid
- Suvodirsen sodiumDystrophin pre-mRNA positive modulator
How its trials ended
410 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 101 whose ending is known, 40% met their primary endpoint, 6% missed it and 54% stopped early.
- Completed, result not reported16039%
- Ongoing11328%
- Met its primary endpoint4010%
- Status unknown369%
- Stopped: other or unclear246%
- Stopped: lack of efficacy123%
- Stopped: sponsor or business decision113%
- Missed its primary endpoint61%
- Stopped: enrollment or feasibility51%
- Stopped: safety2<1%
- Stopped: funding1<1%
| Aug 18, 2026 | A 2-part, randomized, double-blind, placebo-controlled study in participants with Duchenne muscular dystrophy amenable to exon 44 skipping with an initial…ENTR-601-44 | Entrada Therapeutics | Pending |
| Jul 29, 2026 | A phase 2 open-label extension study to assess the safety and efficacy of brogidirsen in boys with Duchenne muscular dystrophy (DMD)Brogidirsen (NS-089/NCNP-02) | NS Pharma Inc | Pending |
| Feb 20, 2026 | A phase 3, randomized, double-blind, placebo-controlled, global study with an open-label extension to evaluate the efficacy and safety of intravenous aoc 1044…Aoc 1044 | Avidity Biosciences | Ongoing |
| Dec 12, 2025 | A phase 2a, randomized, double-blind, placebo-controlled dose comparison and exploratory efficacy study of orally administered SAT-3247 in ambulatory dmd…SAT-3247 | Satellos Bioscience | Ongoing |
| Aug 15, 2025 | A phase 3, multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy of a single intravenous dose of SGT-003 in ambulant…SGT-003 | Solid Biosciences | Ongoing |
| Aug 6, 2025 | A phase 1/2, open-label, dose escalation study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple intravenous doses of bmn…Bmn 351 | BioMarin Pharmaceutical | Ongoing |
| Jan 22, 2025 | A phase 1/2, first in human, multiple-dose, 2-part study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NS-050/NCNP-03 in boys…NS050/NCNP-03 | NS Pharma Inc | Ongoing |
| Jan 20, 2025 | A phase 2 study to assess the efficacy, safety, tolerability, and pharmacokinetics of NS-089/NCNP-02 in boys with Duchenne muscular dystrophy (DMD)Brogidirsen (NS-089/NCNP-02) | NS Pharma Inc | Ongoing |
| Nov 1, 2024 | A phase 1/2/3 open-label, study to evaluate the safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics of intravenous RGX-202 gene therapy in…RGX-202 | REGENXBIO | Ongoing |
| Aug 30, 2024 | A phase 3, multinational, randomized, double-blind, placebocontrolled systemic gene transfer therapy study to evaluate the safety and efficacy of SRP-9001 in…Delandistrogene moxeparvovec (SRP-9001) | Sarepta Therapeutics | Pending |
| Jun 20, 2024 | ElevidysTreatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age for patients who are ambulatory and have a confirmed… | Sarepta Therapeutics, Inc. | Approved |
| Mar 21, 2024 | DuvyzatTreatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older | Italfarmaco SpA | Approved |
| Oct 26, 2023 | AgamreeTreatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older | Catalyst Pharmaceuticals, Inc. | Approved |
| Jun 22, 2023 | ElevidysTreatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the… | Sarepta Therapeutics, Inc. | Approved |
| Feb 25, 2021 | Amondys 45Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45… | Sarepta Therapeutics, Inc. | Approved |
| Aug 12, 2020 | ViltepsoVILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that… | NS Pharma, Inc. | Approved |
| Dec 12, 2019 | Vyondys 53VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene… | Sarepta Therapeutics, Inc. | Approved |
| Jun 7, 2019 | EmflazaEMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. | PTC Therapeutics, Inc. | Approved |
| Feb 9, 2017 | EmflazaTreatment of Duchenne Muscular Dystrophy in patients 5 years of age and older | PTC Therapeutics, Inc. | Approved |
| Sep 19, 2016 | Exondys 51Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51… | Sarepta Therapeutics, Inc. | Approved |
| Oct 24, 2026 | RNA editing antisense oligonucleotide against exon 45 of…Treatment of Duchenne muscular dystrophy | Entrada Therapeutics, Inc. | Designated |
| Sep 22, 2026 | Human umbilical cord derived mesenchymal stem cellsTreatment of Duchenne muscular dystrophy | Signature Biologics | Designated |
| Jun 11, 2026 | TegacoratTreatment of Duchenne muscular dystrophy | GRT Therapeutics, Inc. | Designated |
| Apr 28, 2026 | 4-chloro-N-{4-[(morpholin-4-yl) methyl] phenyl}benzamide…Treatment of Duchenne muscular dystrophy | GEn1E Lifesciences Inc. | Designated |
| Apr 17, 2026 | Small-molecule histone deacetylase 6 inhibitorTreatment of Duchenne muscular dystrophy | Tenaya Therapeutics, Inc. | Designated |
| Jun 6, 2025 | DuvyzatGivinostat · orphan | Italfarmaco S.p.A. | EMA ↗ |
| Dec 14, 2023 | AgamreeVamorolone · orphan | Santhera Pharmaceuticals (Deutschland) GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA